Shortlist

EV/EBIT of 7.7 against a Healthcare median of 20.9 — 63% below peers. Free cash flow yield 13.0%. Trading 71% below its all-time high set 2000-08-25.

At the Healthcare median EV/EBIT of 20.9 instead of its current 7.7, and with earnings unchanged, the equity would be worth about 184% more. That is the size of the gap, not a forecast that it closes.

• ROIC 760% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 48% over three years
• net debt 0.5x EBITDA — balance sheet not forcing anything

Consensus strong buy from 11 analysts, mean target 20.82 USD, 114% above the current price. No revision activity in the last quarter.

Targets spread 96% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Implied upside of 114% is unusually high. The evidence runs the other way here: stocks with the most optimistic targets tend to underperform, because the optimism bias is real and priced-in slowly. Read this as a caution, not an opportunity.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 10.8 against a Industrials median of 21.5 — 50% below peers. Free cash flow yield 8.0%.

At the Industrials median EV/EBIT of 21.5 instead of its current 10.8, and with earnings unchanged, the equity would be worth about 92% more. That is the size of the gap, not a forecast that it closes.

• ROIC 112% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 8/9 — accounts improving year on year
• revenue compounding at 23% over three years
• net debt -0.7x EBITDA — balance sheet not forcing anything

Consensus strong buy from 8 analysts, mean target 89.12 USD, 38% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 13.6 against a Consumer Cyclical median of 19.5 — 30% below peers. Free cash flow yield 8.0%. Trading 33% below its all-time high set 2018-09-27.

At the Consumer Cyclical median EV/EBIT of 19.5 instead of its current 13.6, and with earnings unchanged, the equity would be worth about 43% more. That is the size of the gap, not a forecast that it closes.

• ROIC 51% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt 0.0x EBITDA — balance sheet not forcing anything
• Altman Z 10.6 — outside the distress zone

Consensus buy from 12 analysts, mean target 41.50 USD, 11% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 11.7 against a Technology median of 29.8 — 61% below peers. Free cash flow yield 9.4%. Trading 62% below its all-time high set 2021-11-19.

At the Technology median EV/EBIT of 29.8 instead of its current 11.7, and with earnings unchanged, the equity would be worth about 156% more. That is the size of the gap, not a forecast that it closes.

• ROIC 63% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 11% over three years
• net debt 0.0x EBITDA — balance sheet not forcing anything

Consensus hold from 34 analysts, mean target 269.72 USD, 2% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 70% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

Free cash flow yield 6.0%. Trading 47% below its all-time high set 2024-11-11.

No usable re-rating gap: the multiple is at or above its sector median, or the inputs were missing.

• ROIC 44% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 13% over three years
• net debt -0.0x EBITDA — balance sheet not forcing anything
• Altman Z 4.5 — outside the distress zone

Consensus buy from 7 analysts, mean target 133.57 USD, 28% above the current price. No revision activity in the last quarter.

Targets spread 58% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 6.1 against a Technology median of 29.8 — 80% below peers. Free cash flow yield 13.5%. Trading 57% below its all-time high set 2019-07-10.

At the Technology median EV/EBITDA of 19.5 instead of its current 4.8, and with earnings unchanged, the equity would be worth about n/a more. That is the size of the gap, not a forecast that it closes.

• ROIC 21% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 8% over three years
• net debt 0.7x EBITDA — balance sheet not forcing anything

Consensus buy from 6 analysts, mean target 87.50 USD, 20% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 0.4 against a Technology median of 29.8 — 99% below peers. Free cash flow yield 177.8%. Trading 86% below its all-time high set 2000-03-03.

At the Technology median EV/EBITDA of 19.5 instead of its current 0.3, and with earnings unchanged, the equity would be worth about n/a more. That is the size of the gap, not a forecast that it closes.

• ROIC 33% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 8/9 — accounts improving year on year
• net debt -0.3x EBITDA — balance sheet not forcing anything
• operating margin 17%

mean target 9.67 SEK, 6% below the current price. No revision activity in the last quarter.

Targets spread 35% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Trading 6% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 3.6 against a Financial Services median of 11.0 — 68% below peers. Free cash flow yield 29.7%. Trading 62% below its all-time high set 2025-06-09.

At the Financial Services median EV/EBIT of 11.0 instead of its current 3.6, and with earnings unchanged, the equity would be worth about 97% more. That is the size of the gap, not a forecast that it closes.

• ROIC 144% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 30% over three years
• net debt -4.0x EBITDA — balance sheet not forcing anything
• Altman Z 12.7 — outside the distress zone

Consensus buy from 14 analysts, mean target 49.79 USD, 74% above the current price. No revision activity in the last quarter.

Targets spread 110% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Implied upside of 74% is unusually high. The evidence runs the other way here: stocks with the most optimistic targets tend to underperform, because the optimism bias is real and priced-in slowly. Read this as a caution, not an opportunity.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 4.9 against a Financial Services median of 11.0 — 56% below peers. Free cash flow yield 24.6%.

At the Financial Services median EV/EBIT of 11.0 instead of its current 4.9, and with earnings unchanged, the equity would be worth about 94% more. That is the size of the gap, not a forecast that it closes.

• ROIC 28% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 26% over three years
• operating margin 27%

Consensus buy from 19 analysts, mean target 111.87 USD, 13% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Not trading at a discount to its sector on any measure this tool computes. That is a fact about the price, not a judgement about the company — good businesses spend most of their lives fairly priced.

At the Technology median EV/EBIT of 29.8 instead of its current 29.7, and with earnings unchanged, the equity would be worth about 0% more. That is the size of the gap, not a forecast that it closes.

• ROIC 40% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 13% over three years
• net debt 0.1x EBITDA — balance sheet not forcing anything

Consensus strong buy from 34 analysts, mean target 312.75 USD, 24% above the current price. No revision activity in the last quarter.

Targets spread 75% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 10.7 against a Technology median of 29.8 — 64% below peers. Free cash flow yield 12.0%. Trading 32% below its all-time high set 2026-06-03.

At the Technology median EV/EBIT of 29.8 instead of its current 10.7, and with earnings unchanged, the equity would be worth about 157% more. That is the size of the gap, not a forecast that it closes.

• ROIC 30% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt -1.4x EBITDA — balance sheet not forcing anything
• Altman Z 12.2 — outside the distress zone

Consensus buy from 4 analysts, mean target 165.00 USD, 36% above the current price. No revision activity in the last quarter.

Targets spread 42% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 16.2 against a Technology median of 29.8 — 46% below peers. Free cash flow yield 10.2%. Trading 78% below its all-time high set 2021-08-24.

At the Technology median EV/EBIT of 29.8 instead of its current 16.2, and with earnings unchanged, the equity would be worth about 75% more. That is the size of the gap, not a forecast that it closes.

• ROIC 177% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 38% over three years
• net debt -1.8x EBITDA — balance sheet not forcing anything
• Altman Z 4.6 — outside the distress zone

Consensus strong buy from 10 analysts, mean target 18.35 USD, 29% above the current price. Revisions over the last quarter have been net positive, which is the part of analyst output the evidence actually supports.

Targets spread 35% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.